# ADCT — Adc Therapeutics SA · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ADCT  
**Sources:** 17  
**Published:** 2026-10-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-adct-adc-therapeutics-sa-catalysts-narrative-risks-5853

---

## Company Snapshot

ADC Therapeutics SA is a commercial-stage antibody drug conjugate (ADC) company headquartered in Lausanne, Switzerland, with operations in New Jersey, focused primarily on ZYNLONTA (loncastuximab tesirine-lpyl) for diffuse large B-cell lymphoma (DLBCL). [[1]](https://www.nasdaq.com/press-release/adc-therapeutics-reports-second-quarter-2026-financial-results-and-provides) [[9]](https://finance.yahoo.com/healthcare/articles/adc-therapeutics-participate-2026-cantor-111500949.html) It trades on the NYSE under ticker ADCT. [[9]](https://finance.yahoo.com/healthcare/articles/adc-therapeutics-participate-2026-cantor-111500949.html) As of the October 2, 2026 close, the stock traded near ~$1.13 with a market capitalization of approximately $144 million. [[8]](https://askthedate.com/America/New_York/en/earnings-calendar/2026-11-10/ADCT/) [[12]](https://stockanalysis.com/stocks/adct/forecast/) [[16]](https://tickernerd.com/stock/adct-forecast/)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-adct-adc-therapeutics-sa-catalysts-narrative-risks-5853 (free to sign up)._
